Research programme: DNA repair inhibitors - Ignyta/Cancer Research Technology

Drug Profile

Research programme: DNA repair inhibitors - Ignyta/Cancer Research Technology

Alternative Names: RXDX-108; TEV-44229

Latest Information Update: 29 Jun 2016

Price : $50

At a glance

  • Originator Cancer Research Technology; Teva Pharmaceutical Industries
  • Developer Cancer Research Technology; Ignyta
  • Class Small molecules
  • Mechanism of Action DNA repair inhibitors; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Mar 2016 Ignyta has patents pending for RXDX 108 in USA (Ignyta 10-K, March 2016)
  • 26 Feb 2016 Discontinued - Preclinical for Cancer in United Kingdom, USA (unspecified route)
  • 17 Mar 2015 Ignyta acquires RXDX 108 and other next generation atypical protein kinase C iota inhibitors from Teva Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top